Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Novartis
Farmers Insurance
Merck
Chubb
Daiichi Sankyo
Covington
AstraZeneca
UBS
US Army

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,414,126

« Back to Dashboard

Summary for Patent: 6,414,126
Title: C-aryl glucoside SGLT2 inhibitors and method
Abstract:SGLT2 inhibiting compounds are provided having the formula ##STR1## where R.sup.1, R.sup.2, and R.sup.2a are independently hydrogen, OH, OR.sup.5, lower alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2 Aryl, lower alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2 R.sup.5b, --CO.sub.2 H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6 R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2 R.sup.5d, --NHSO.sub.2 Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2 R.sup.5g, --SO.sub.2 Aryl, or a five, six or seven membered heterocycle, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently lower alkyl; R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH.sub.2).sub.n where n is 0-3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Inventor(s): Ellsworth; Bruce (Princeton, NJ), Washburn; William N. (Titusville, NJ), Sher; Philip M. (Plainsboro, NJ), Wu; Gang (Princeton, NJ), Meng; Wei (Pennington, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/679,027
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,414,126

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-005 Jul 28, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-002 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-001 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-004 Oct 29, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab XIGDUO XR dapagliflozin propanediol; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205649-003 Oct 29, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF TYPE 2 DIABETES MELLITUS ➤ Subscribe
Astrazeneca Ab FARXIGA dapagliflozin propanediol TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,414,126

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,515,117 C-aryl glucoside SGLT2 inhibitors and method ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,414,126

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 026024 ➤ Subscribe
Argentina 040032 ➤ Subscribe
Austria 295848 ➤ Subscribe
Austria 353334 ➤ Subscribe
Australia 2003237886 ➤ Subscribe
Australia 781009 ➤ Subscribe
Australia 7848300 ➤ Subscribe
Brazil 0014722 ➤ Subscribe
Brazil 0311323 ➤ Subscribe
Canada 2388818 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
McKesson
Queensland Health
Cantor Fitzgerald
Farmers Insurance
Argus Health
Federal Trade Commission
Healthtrust
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot